PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19464306-6 2009 Moreover, contractions induced by oxytocin or different prostaglandins (PGF(2alpha), PGE(2), and a prostaglandin analogue, misoprostol) were inhibited rather than increased by RU 486. Misoprostol 123-134 oxytocin/neurophysin I prepropeptide Homo sapiens 34-42 20347088-7 2010 CONCLUSION: A 50-microg intravaginal application of misoprostol before starting the oxytocin infusion is a more effective method of labor induction than an oxytocin infusion alone for our study population. Misoprostol 52-63 oxytocin/neurophysin I prepropeptide Homo sapiens 156-164 11883268-15 2001 In misoprostol treated group patients required less analgetics then in oxytocin treated group. Misoprostol 3-14 oxytocin/neurophysin I prepropeptide Homo sapiens 71-79 12789117-10 2001 In the gestational age before 28 weeks, the induction to delivery interval in oxytocin group, was more than twice that used in misoprostol. Misoprostol 127-138 oxytocin/neurophysin I prepropeptide Homo sapiens 78-86 15738009-1 2005 OBJECTIVE: To determine whether a single outpatient dose of intravaginal misoprostol (versus intracervical dinoprostone gel) reduces the oxytocin use for induction. Misoprostol 73-84 oxytocin/neurophysin I prepropeptide Homo sapiens 137-145 15738009-9 2005 RESULTS: A single dose of misoprostol significantly decreased the cumulative dose of oxytocin, the cumulative time of oxytocin administration, and the dose intensity of oxytocin (dose divided by time). Misoprostol 26-37 oxytocin/neurophysin I prepropeptide Homo sapiens 85-93 15738009-9 2005 RESULTS: A single dose of misoprostol significantly decreased the cumulative dose of oxytocin, the cumulative time of oxytocin administration, and the dose intensity of oxytocin (dose divided by time). Misoprostol 26-37 oxytocin/neurophysin I prepropeptide Homo sapiens 118-126 15738009-9 2005 RESULTS: A single dose of misoprostol significantly decreased the cumulative dose of oxytocin, the cumulative time of oxytocin administration, and the dose intensity of oxytocin (dose divided by time). Misoprostol 26-37 oxytocin/neurophysin I prepropeptide Homo sapiens 118-126 15738009-15 2005 CONCLUSION: A single dose of misoprostol administered in the outpatient setting significantly decreases oxytocin use, largely due to labor within the ripening period. Misoprostol 29-40 oxytocin/neurophysin I prepropeptide Homo sapiens 104-112 11034716-14 2000 MAIN RESULTS: One trial with 80 randomised women with prelabour rupture of membranes at term showed that, compared with placebo, oral misoprostol reduces the need for oxytocin infusion from 51 percent to 13 percent (relative risk 0.25, 95% confidence interval 0.1 to 0.6) and shortens delivery time by 8.7 hours (95% CI 6.0 to 11.3). Misoprostol 134-145 oxytocin/neurophysin I prepropeptide Homo sapiens 167-175 11405987-11 2001 MAIN RESULTS: One trial with 80 randomised women with prelabour rupture of membranes at term showed that, compared with placebo, oral misoprostol reduces the need for oxytocin infusion from 51 percent to 13 percent (relative risk 0.25, 95% confidence interval (CI) 0.1 to 0.6) and shortens delivery time by 8.7 hours (95% CI 6.0 to 11.3). Misoprostol 134-145 oxytocin/neurophysin I prepropeptide Homo sapiens 167-175 10796260-8 2000 In one placebo trial, oral misoprostol reduced the need for oxytocin infusion and shortened delivery time in women with prelabour rupture of membranes at term. Misoprostol 27-38 oxytocin/neurophysin I prepropeptide Homo sapiens 60-68 10796260-9 2000 In another trial, compared to vaginal prostaglandins, oral misoprostol reduced the need for oxytocin (relative risk 0.62, 95% confidence interval 0.47 to 0.82). Misoprostol 59-70 oxytocin/neurophysin I prepropeptide Homo sapiens 92-100 9699753-0 1998 Rectally administered misoprostol for the treatment of postpartum hemorrhage unresponsive to oxytocin and ergometrine: a descriptive study. Misoprostol 22-33 oxytocin/neurophysin I prepropeptide Homo sapiens 93-101 19439793-9 1999 The need for oxytocin was 40% in the misoprostol and 71% in the dinopro notstone group (p<0.05). Misoprostol 37-48 oxytocin/neurophysin I prepropeptide Homo sapiens 13-21 9699753-6 1998 Rectally administered misoprostol appears to be an effective treatment for postpartum hemorrhage unresponsive to oxytocin and ergometrine; therefore, it might be an alternative to parenteral prostaglandins or at least minimize the number of women requiring this invasive treatment. Misoprostol 22-33 oxytocin/neurophysin I prepropeptide Homo sapiens 113-121 8369246-7 1993 MAIN OUTCOME MEASURES: Efficacy of the misoprostol was measured by the increase in the Bishop score 12 h after giving the treatment, the time between insertion and delivery, the need for oxytocin, and the outcome of the pregnancy. Misoprostol 39-50 oxytocin/neurophysin I prepropeptide Homo sapiens 187-195 34155622-18 2021 Oral misoprostol versus intravenous oxytocin (6 trials; 737 women, 200 with ruptured membranes) Misoprostol may make little or no difference to vaginal births within 24 hours (RR 1.12, 95% CI 0.95 to 1.33; 3 trials; 466 women; low-certainty evidence), but probably results in fewer caesarean sections (RR 0.67, 95% CI 0.50 to 0.90; 6 trials; 737 women; moderate-certainty evidence). Misoprostol 96-107 oxytocin/neurophysin I prepropeptide Homo sapiens 36-44 30487496-7 2018 In oxytocin group 30(96.8) patients received ergometrin and 26(83.9) patients received misoprostol. Misoprostol 87-98 oxytocin/neurophysin I prepropeptide Homo sapiens 3-11 26120407-11 2013 Number of abortion in misoprostol group was more than oxytocin group (P<0.001) and duration of abortion also was shorter than oxytocin in misoprostol group (P<0.001). Misoprostol 141-152 oxytocin/neurophysin I prepropeptide Homo sapiens 129-137 24734184-2 2014 Studies suggest that the use of misoprostol may be beneficial in clinical settings where oxytocin is unavailable. Misoprostol 32-43 oxytocin/neurophysin I prepropeptide Homo sapiens 89-97 24971122-9 2013 Oxytocin was required only in misoprostol group. Misoprostol 30-41 oxytocin/neurophysin I prepropeptide Homo sapiens 0-8 26663995-6 2015 CONCLUSION: The use of combined lower dose of misoprostol-oxytocin significantly reduced the amount of blood loss during and after the lower segment cesarean section compared to higher dose of oxytocin and misoprostol alone, and its use was not associated with any serious side effects. Misoprostol 46-57 oxytocin/neurophysin I prepropeptide Homo sapiens 58-66 26663995-6 2015 CONCLUSION: The use of combined lower dose of misoprostol-oxytocin significantly reduced the amount of blood loss during and after the lower segment cesarean section compared to higher dose of oxytocin and misoprostol alone, and its use was not associated with any serious side effects. Misoprostol 46-57 oxytocin/neurophysin I prepropeptide Homo sapiens 193-201 26596797-8 2015 Oxytocin/misoprostol was found to be cost saving (US$320) compared to oxytocin/no treatment. Misoprostol 9-20 oxytocin/neurophysin I prepropeptide Homo sapiens 0-8 26596797-9 2015 If misoprostol is used in both the hospital and community setting compared with no treatment (i.e. oxytocin not available in the hospital setting), 37 cases of PPH could be prevented; ten fewer women would require additional uterotonics; and six fewer women a blood transfusion. Misoprostol 3-14 oxytocin/neurophysin I prepropeptide Homo sapiens 99-107 26596797-13 2015 CONCLUSIONS: Our findings confirm that, even though misoprostol is not the optimum choice in the prevention of PPH, misoprostol could be an effective and cost-saving choice where oxytocin is not or cannot be used due to a lack of skilled birth attendants, inadequate transport and storage facilities or where a quality assured oxytocin product is not available. Misoprostol 116-127 oxytocin/neurophysin I prepropeptide Homo sapiens 327-335 25055933-11 2015 CONCLUSIONS: Sublingual misoprostol and intracervical dinoprostone at the dose studied are equally efficacious in achieving spontaneous vaginal delivery, reduction in induction-delivery interval and in reducing the need for oxytocin, in women after 34 weeks gestation with rupture of membranes. Misoprostol 24-35 oxytocin/neurophysin I prepropeptide Homo sapiens 224-232 26120407-14 2013 CONCLUSION: This study demonstrated that misoprostol is effective than oxytocin in termination of pregnancy but with attention to limitation of this study include of limited abortion causes due to legal laws, additional studies on different doses of misoprostol and oxytocin due to achieve to suitable regimen with lower side effects recommended. Misoprostol 41-52 oxytocin/neurophysin I prepropeptide Homo sapiens 266-274 21780543-4 2011 Maximum improvement (p < 0.05) in Bishop"s score and minimum oxytocin requirement (p < 0.05) was seen with misoprostol 50 microg. Misoprostol 113-124 oxytocin/neurophysin I prepropeptide Homo sapiens 64-72 22901709-3 2013 Of the 2, misoprostol is inferior: 2 recent well-done randomized trials with enrollment of more than 2200 patients demonstrated that, in situations in which prophylactic oxytocin has already been utilized, additional oxytocin is as effective as or better than misoprostol in terminating bleeding, while avoiding the high rate of fever (22-58%) associated with misoprostol. Misoprostol 10-21 oxytocin/neurophysin I prepropeptide Homo sapiens 217-225 26852436-0 2012 EFFECT OF PRE-OPERATIVE SUB-LINGUAL MISOPROSTOL VERSUS INTRAVENOUS OXYTOCIN ON CAESAREAN OPERATION BLOOD LOSS. Misoprostol 36-47 oxytocin/neurophysin I prepropeptide Homo sapiens 67-75 26852436-6 2012 The drop in haematocrit was significantly lower in misoprostol group than the oxytocin group, (400 mug-misoprostol versus oxytocin: 1.88 versus 3.04; p = 0.0001). Misoprostol 51-62 oxytocin/neurophysin I prepropeptide Homo sapiens 122-130 21780543-6 2011 CONCLUSION: Intravaginal misoprostol 50 microg administered 6 hourly appears to be most effective as it has least induction to delivery time, has maximum improvement in Bishop"s score, least oxytocin requirement without any increase in complication rate. Misoprostol 25-36 oxytocin/neurophysin I prepropeptide Homo sapiens 191-199